CA2616997C — Dry powder inhalers that inhibit agglomeration, related devices and methods
Assigned to Oriel Therapeutics Inc · Expires 2014-12-23 · 11y expired
What this patent protects
The disclosure describes methods and inhalers (50) that deagglomerate dry powder using inspiratory effort of a user of an inhaler (50). Inhaler fin (75) and mesh configurations are described that facilitate deagglomeration. At least in steady state conditions, a dry powder and ai…
USPTO Abstract
The disclosure describes methods and inhalers (50) that deagglomerate dry powder using inspiratory effort of a user of an inhaler (50). Inhaler fin (75) and mesh configurations are described that facilitate deagglomeration. At least in steady state conditions, a dry powder and airflow pattern can be generated having turbulence with flow vortices, some of which may have a vortex having an axis of rotation that extends in an inspiratory flow direction while others may have a vortex that is substantially orthogonal to the inspiratory flow direction in an inspiratory airflow path (12), as an amount of dry powder travels through the inhaler (50) to thereby deagglomerate the dry powder without trapping undue amounts of the dry powder during inhalation.
Drugs covered by this patent
- Remodulin (TREPROSTINIL) · United Therap
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.